Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

France Implements New Early Access Pathway For Innovative Medicines

Current Procedures Have Become Too Complex, Says Health Ministry

Executive Summary

Reforms to the French early access processes will make reimbursement decisions more predictable and bring greater consistency into the medicinal product pathway says the French pharmaceutical industry body Leem. Others, though, say the system is too complicated and lacks clarity in a number of areas.

You may also be interested in...



Access To Innovation Looking Brighter In France

French Biotech In Focus: The French biotech industry body France Biotech says that the authorities are making good progress in reducing the time taken to get new medicines on the market, but that low drug prices and high industry taxes remain key challenges for the industry.

UK Avoids 'Cliff Edge' By Extending EU Drug Approval Reliance Procedure

The UK drugs regulator says it needs to make sure that companies do not “deprioritize” GB approval applications while a new “international reliance framework” is being developed.

Stakeholders Must ‘Fully Engage’ If WHO’s Medicines Access Platform Is To Succeed

Delegates at the European Health Forum Gastein outlined the challenges facing an international effort to improve access to costly new medicines across the World Health Organization’s European region, insisting that the key issues had to be addressed “collectively” and without “finger pointing.”

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS144584

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel